HMNC Brain Health’s 13-slide deck outlines a sophisticated approach to precision psychiatry, targeting the 320 million people suffering from depression globally. By pairing proprietary antidepressants with companion diagnostics (CDx), the company aims to reduce the 'trial-and-error' nature of mental health treatment. The deck highlights a lead candidate, Nelivabon, which is currently in a Phase II trial (OLIVE) with an expected readout in H2 2024. The strategy leverages previously de-risked compounds, such as those from Sanofi, and applies genomic analysis to identify patients most likely to…
Key takeaways
- The company addresses a massive market of 320 million depression sufferers, noting that 72 out of 100 patients fail first-line treatment (Slide 4).
- HMNC aims for a 7-day turnaround from patient contact to the start of personalized treatment using genomic analysis (Slide 6).
- The pipeline includes three primary programs: Nelivabon (MDD), Cortibon (MDD), and Ketabon (TRD), with estimated market approvals ranging from 2027 to 2030+ (Slide 8).
- Nelivabon (BH-200) is a V1b receptor antagonist previously developed by Sanofi and tested in over 900 subjects, providing significant safety de-risking (Slide 10).
- The OLIVE Phase II trial is a multicenter, double-blind study involving 324 randomized patients with a readout expected in H2 2024 (Slide 10).
- The company utilizes a 'Co-Development' model where the drug (Rx) and the diagnostic (CDx) are developed in parallel (Slide 8).
- HMNC maintains a dual presence with offices in Munich, Germany, and New York, USA (Slide 12).
- The deck lacks a specific 'Ask' slide, cap table details, or a breakdown of how the $14M Series B funds will be allocated across the three programs.
Executive Summary: Precision Psychiatry at Scale
HMNC Brain Health is positioning itself at the intersection of biotechnology and personalized medicine. As reported by Business Insider, the company raised a $14M Series B in 2024 to further its mission of bringing precision therapeutics to the mental health space. The deck focuses heavily on the clinical validation of their 'companion diagnostic' (CDx) approach, which seeks to solve the 'trial-and-error' problem inherent in modern antidepressant prescriptions. By using genomic biomarkers to predict patient response, HMNC aims to transform depression treatment from a broad-spectrum guessing game into a targeted medical intervention.
Slide 1-2: Introduction and Compliance
The deck opens with a portrait of Maximilian Döbler, the Chief Business Officer, establishing a point of contact for the presentation. Slide 2 is a standard legal disclaimer. It explicitly states that the content is for 'obtaining feedback from market experts' and does not constitute an offer to enter into an investment. This is standard for biotech decks which often circulate in highly regulated environments where forward-looking statements regarding clinical outcomes must be carefully couched in legal protections.
Slide 4: The Scale of the Problem
Slide 4 establishes the 'Why Now' and the total addressable market. It cites that 320 million people suffer from depression today and predicts that depression will be the 'global leading burden of disease' by 2030. The most compelling data point on this slide is the failure rate of current treatments: out of 100 patients, 72 fail to achieve remission after the first line of treatment, and 34 fail to remit even after multiple lines. This sets the stage for a precision medicine solution by highlighting the inadequacy of the current 'one-size-fits-all' standard of care.
Slide 6: The Patient Journey and AI Integration
This slide illustrates the operational flow of the HMNC solution. The process begins with a healthcare practitioner (HCP) obtaining a blood sample. This sample undergoes genomic analysis for specific biomarkers, such as single nucleotide polymorphisms. HMNC’s CDx then recommends an 'optimal compound fit' for the patient. A key metric mentioned here is the '7 days' target from patient contact to the start of personalized treatment. The slide also mentions 'Algorithm Optimization,' suggesting that an AI platform will improve its predictive power as more patient data is collected, creating a data moat for the company.
Slide 8: The Co-Development Pipeline
Slide 8 provides a comprehensive view of the company’s assets. It lists three main programs:
Nelivabon (BH-200 & V1bCDx): Targeting Major Depressive Disorder (MDD) with an estimated market approval in 2028. The Rx is in Phase II, and the CDx is in clinical validation. · Cortibon (E2009 & CRHR1CDx): Targeting MDD with an estimated approval in 2030+. This is in earlier stages (Phase I for Rx, Prototype for CDx). · Ketabon (KET-01): A joint venture with Develco Pharma targeting Treatment-Resistant Depression (TRD) using racemic ketamine, with an estimated approval in 2027.
This slide is crucial because it shows the company is not a 'single-shot-on-goal' biotech; it has a diversified pipeline at various stages of the FDA/EMA approval process.
Slide 10: Clinical De-risking and the OLIVE Trial
HMNC focuses on its lead candidate, Nelivabon, in Slide 10. The company highlights that the compound was previously developed by Sanofi, which tested it in over 900 subjects. This is a significant 'de-risking' signal for investors, as it suggests the safety profile is well-understood, allowing HMNC to focus on efficacy within a specific biomarker-positive population. The slide details the 'OLIVE' trial: a multicenter, double-blind, placebo-controlled Phase II trial with 324 patients. The timeline is clear: H1 2023 randomization and an H2 2024 readout. For a Series B investor, this readout represents the primary value inflection point.
Slide 12: Geographic Footprint and Contact
The final slide provides contact information for Dr. Maximilian Doebler and lists two primary locations: Munich, Germany, and New York, USA. This dual-presence suggests an ambition to capture both the European and North American markets, which is necessary for a biotech company seeking a global standard of care in psychiatry.
What HMNC Brain Health Does Well
The deck excels at explaining a complex scientific concept—precision psychiatry—in a way that is accessible to generalist investors while remaining rigorous enough for specialists. The use of the '100 patients' infographic on Slide 4 is an excellent way to visualize the 'unmet medical need.' Furthermore, the pipeline slide (Slide 8) is a model of clarity, showing the parallel development of the drug and the diagnostic, which is the core of their business model. The emphasis on 'de-risking' through the Sanofi partnership is a strong tactical move, as it addresses the primary fear of biotech investors: unexpected toxicity or safety failures in late-stage trials.
What is Missing from the Deck
Despite raising $14M, the deck provided is surprisingly light on corporate and financial specifics. There is no 'Ask' slide detailing how the $14M will be spent or what milestones the Series B is intended to reach. There is also no team slide in this sequence, which is a major omission for a biotech company where the scientific advisory board and management’s clinical track record are paramount. Additionally, the deck lacks a competitive landscape . While they mention the failure of 'standard' antidepressants, they do not address other precision psychiatry startups or digital health companies moving into the biomarker space. Finally, there is no mention of intellectual property (IP) ; investors would want to know the patent life remaining on the acquired Sanofi compounds and the proprietary nature of the CDx algorithms.
Founder Takeaways: Lessons from HMNC
Leverage 'Past Failures' as Assets: HMNC shows how to take a compound that may not have met broad endpoints in a previous life (Sanofi) and give it a second, more profitable life by narrowing the patient population. If you are in biotech, look for ways to 'de-risk' by using existing safety data. Visualize the Journey: Slide 6 is a great example of how to show a complex service delivery model. By mapping out the 'Patient’s Mental Health Journey,' they make the integration of AI and genomics feel like a seamless part of a doctor’s visit rather than a futuristic abstraction. Clear Inflection Points: The deck is very clear about when the next big news will break (H2 2024). Founders should always clearly mark their next major clinical or commercial milestone so investors can calibrate their risk-reward calculations.
Frequently asked questions
- What is the primary value proposition of HMNC Brain Health?
- HMNC Brain Health focuses on precision psychiatry. Their core value proposition is reducing the high failure rate of antidepressants by using companion diagnostics (CDx) to match patients with the specific compound that fits their personal biology. This aims to achieve higher remission rates and less trial-and-error for the 320 million people suffering from depression.
- What stage is their lead candidate, Nelivabon?
- Nelivabon (BH-200) is currently in a Phase II randomized clinical trial called OLIVE. The trial is multicenter and double-blind, involving 324 patients. According to slide 10, the first patients were randomized in H1 2023, and a clinical readout is expected in the second half of 2024.
- How does HMNC de-risk its drug development process?
- The company de-risks development by acquiring or partnering on compounds that have already undergone significant clinical testing. For example, Nelivabon was previously under development by Sanofi and tested in over 900 subjects, establishing a safety profile before HMNC applied its precision diagnostic layer to improve efficacy outcomes.
- What are the key milestones mentioned in the deck?
- Key milestones include the H2 2024 readout for the Nelivabon Phase II trial, an estimated market approval for Ketabon in 2027, and estimated market approval for Nelivabon in 2028. The Cortibon program is slated for approval in 2030 or later.
- What information is missing from this pitch deck?
- The deck is missing several standard venture components: a detailed team slide (beyond the CBO), a specific funding 'Ask' (how much they want and what for), a competitive landscape analysis, and financial projections or unit economics for the diagnostic tests.
